Transaction overview
01Lantern Pharma Inc. completed a $4.0M registered direct at $1.09 per share. Rodman & Renshaw LLC acted as exclusive placement agent for the financing.
- Financing type
- Registered Direct
- Announcement date
- Sep 29, 2026
- Pricing date
- Sep 29, 2026
- Closing date
- Sep 30, 2026
- Filing date
- Sep 30, 2026
- Status
- Closed
- Market cap before announcement
- $13.5M
- Prior closing price
- $1.09
- Raise as % of market cap
- 29.5%
Market data · FMP
- Historical market cap
- $13,541,259
- Market date
- Sep 28, 2026
- Closing price
- $1.09
- Latest reported shares outstanding
- 12,759,146
- Latest reported float shares
- 9,594,424
- Share-data date
- Oct 1, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 2, 2026.
Financial Modeling Prep ↗Financing terms
02Equity
- Common shares issued
- 1,469,725
- Price per share
- $1.09
- Pre-funded warrants
- 2,200,000
- Pre-financing shares disclosed in filing
- —
- Shares outstanding after financing
- —
Investor warrants
- Warrant shares
- 3,669,725
- Cash exercise price
- $1.09
- Term
- Five years after the stockholder-approval initial exercise date; not five years from closing.
- Initial exercisability
- —
- Beneficial ownership limits
- —
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: —
Fees & transaction economics
03- Placement agent / underwriting fee
- 7%
- Agent fee amount
- $280,000
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
7% cash placement fee; agent warrants equal to 5% of securities sold, with the exact whole-share allocation undisclosed; expense reimbursement amount undisclosed. A separate 3% fee applies to future cash exercises of investor warrants.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
Form of agent warrant and 8-K: five years from stockholder approval. Prospectus describes five years from commencement of sales; conflicting wording is retained for follow-up. Exact expiration date remains unknown.
at any time on or after the Stockholder Approval Date (the “ Initial Exercise Date ”) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the Initial Exercise Date (the “ Termination Date ”) but not thereafterOriginal source ↗
7% cash placement fee; agent warrants equal to 5% of securities sold, with the exact whole-share allocation undisclosed; expense reimbursement amount undisclosed. A separate 3% fee applies to future cash exercises of investor warrants.
In consideration for the Placement Agent serving as the placement agent for the Offering, the Company paid the Placement Agent a cash fee equal to 7% of the aggregate gross proceeds of the Offering and reimbursed the Placement Agent for certain expenses and legal fees. In addition, the Company issued to the Placement Agent or its designees warrants to purchase 5% of the Common Shares (or Pre-Funded Warrants in lieu thereof) sold in the Offering (the “Placement Agent Warrants”). The Placement Agent Warrants have substantially the same terms as the Purchase Warrants except that the Placement Agent Warrants have an exercise price of $1.3625 per share (125% of Common Share purchase price) and will expire on the fifth anniversary of Stockholder Approval. The Company has agreed to file a resale registration statement with the Securities and Exchange Commission for the shares underlying the Placement Agent Warrants. The Company has also agreed to pay the Placement Agent a cash fee of 3.0% of the gross exercise price paid in cash with respect to the exercise of any Purchase Warrants issued in the concurrent private placement.Original source ↗
Five years after the stockholder-approval initial exercise date; not five years from closing.
The Purchase Warrants will become exercisable upon receipt of stockholder approval, or Stockholder Approval, of the issuance of the shares of common stock issuable upon exercise of the Purchase Warrants and expire five years following the initial exercise date.Original source ↗
FMP reported market cap; as of 2026-09-28.
{"provider": "FMP", "symbol": "LTRN", "date": "2026-09-28", "marketCap": 13541259}Original source ↗